# Hyperthermia Combined With Immunotherapy in the Treatment of Abdominal and Pelvic Malignancies or Metastases

> **NCT03757858** · PHASE1,PHASE2 · COMPLETED · sponsor: **Capital Medical University** · enrollment: 40 (actual)

## Conditions studied

- Cancer
- Abdominal Cancer
- Pelvic Cancer
- Metastatic Cancer
- Peritoneal Metastases
- Liver Metastases

## Interventions

- **DEVICE:** Thermotron RF-8
- **BIOLOGICAL:** Adoptive cellular Immunotherapy
- **DRUG:** Anti-PD-1 antibody
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT03757858
- **Lead sponsor:** Capital Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-01
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-06-01
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2024-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03757858

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03757858, "Hyperthermia Combined With Immunotherapy in the Treatment of Abdominal and Pelvic Malignancies or Metastases". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03757858. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*